Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for CCCC.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2019. Start Trial.
Date Value
June 30, 2026 33.72M
March 31, 2026 0.462M
December 31, 2025 118.67M
September 30, 2025 7.773M
June 30, 2025 0.00
March 31, 2025 -0.046M
December 31, 2024 0.112M
September 30, 2024 10.51M
June 30, 2024 0.135M
March 31, 2024 34.58M
December 31, 2023 57.67M
September 30, 2023 -10.75M
June 30, 2023 -0.746M
March 31, 2023 -0.684M
Date Value
December 31, 2022 0.047M
September 30, 2022 0.361M
June 30, 2022 0.259M
March 31, 2022 0.48M
December 31, 2021 0.466M
September 30, 2021 0.584M
June 30, 2021 170.50M
March 31, 2021 -0.151M
December 31, 2020 194.05M
September 30, 2020
June 30, 2020
March 31, 2020 0.156M
December 31, 2019 0.078M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Beam Therapeutics, Inc. 7.523M
Rallybio Corp. 0.131M
Q32 Bio, Inc. 58.59M
Arrowhead Pharmaceuticals, Inc. -0.449M
Oncolytics Biotech, Inc. 6.704M